J 2022

Comparing Digital Therapeutic Intervention with an Intensive Obesity Management Program: Randomized Controlled Trial

MORAVCOVÁ, Katarína, Martina KARBANOVÁ, Maxi Pia BRETSCHNEIDER, Markéta SOVOVÁ, Jaromir OZANA et. al.

Basic information

Original name

Comparing Digital Therapeutic Intervention with an Intensive Obesity Management Program: Randomized Controlled Trial

Authors

MORAVCOVÁ, Katarína (203 Czech Republic, guarantor), Martina KARBANOVÁ (203 Czech Republic, belonging to the institution), Maxi Pia BRETSCHNEIDER, Markéta SOVOVÁ (203 Czech Republic), Jaromir OZANA (203 Czech Republic) and Eliska SOVOVA (203 Czech Republic)

Edition

Nutrients, Basel, MDPI, 2022, 2072-6643

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30308 Nutrition, Dietetics

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 5.900

RIV identification code

RIV/00216224:14110/22:00125801

Organization unit

Faculty of Medicine

UT WoS

000801761100001

Keywords in English

obesity; diabetes mellitus type 2; prevention; digital therapeutics; mobile application; randomized controlled trial; lifestyle intervention; metabolic syndrome; insulin resistance

Tags

Tags

International impact, Reviewed
Změněno: 25/1/2023 09:59, Mgr. Tereza Miškechová

Abstract

V originále

In this study, we evaluated whether the digital program Vitadio achieves comparable results to those of an intensive in-person lifestyle intervention in obesity management. This is a 12-month prospective, randomized controlled trial. Obese patients with insulin resistance, prediabetes or type 2 diabetes were included. The intervention group (IG) used Vitadio. The control group (CG) received a series of in-person consultations. Body weight and various metabolic parameters were observed and analyzed with ANOVA. The trial is ongoing and the presented findings are preliminary. Among 100 participants (29% men; mean age, 43 years; mean BMI, 40.1 kg/m2), 78 completed 3-month follow-up, and 51 have completed the 6-month follow-up so far. Participants significantly (p < 0.01) reduced body weight at 3 months (IG: −5.9 ± 5.0%; CG: −4.2 ± 5.0%) and 6 months (IG: −6.6±6.1%; CG: −7.1 ± 7.1%), and the difference between groups was not significant. The IG achieved favorable change in body composition; significant improvement in TAG (−0.6 ± 0.9 mmol/l, p < 0.01), HDL (0.1 ± 0.1%, p < 0.05), HbA1c (−0.2 ± 0.5%, p < 0.05) and FG (−0.5 ± 1.5 mmol/l, p < 0.05); and a superior (p = 0.02) HOMA-IR reduction (−2.5 ± 5.2, p < 0.01). The digital intervention achieved comparable results to those of the intensive obesity management program. The results suggest that Vitadio is an effective tool for supporting patients in obesity management and diabetes prevention.